

# Gavin J Kilpatrick

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1778549/gavin-j-kilpatrick-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73  
papers

5,766  
citations

38  
h-index

75  
g-index

75  
ext. papers

6,143  
ext. citations

6.1  
avg, IF

5.08  
L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 73 | Identification and distribution of 5-HT <sub>3</sub> receptors in rat brain using radioligand binding. <i>Nature</i> , <b>1987</b> , 330, 746-8  | 50.4 | 814       |
| 72 | Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1997</b> , 94, 14854-8  | 11.5 | 309       |
| 71 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. <i>Neuroscience Letters</i> , <b>1984</b> , 50, 85-90  | 3.3  | 304       |
| 70 | A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 4938-43   | 11.5 | 260       |
| 69 | Development of a radioligand binding assay for 5-HT <sub>4</sub> receptors in guinea-pig and rat brain. <i>British Journal of Pharmacology</i> , <b>1993</b> , 109, 618-24   | 8.6  | 245       |
| 68 | Binding of the 5-HT <sub>3</sub> ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. <i>European Journal of Pharmacology</i> , <b>1989</b> , 159, 157-64   | 5.3  | 201       |
| 67 | Histamine H <sub>3</sub> receptors modulate the release of [3H]-acetylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H <sub>3</sub> receptor subtypes. <i>British Journal of Pharmacology</i> , <b>1992</b> , 107, 919-23                    | 8.6  | 199       |
| 66 | 5-HT <sub>3</sub> receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. <i>British Journal of Pharmacology</i> , <b>1989</b> , 97, 247-55   | 8.6  | 189       |
| 65 | 5-HT <sub>3</sub> receptors. <i>Medicinal Research Reviews</i> , <b>1990</b> , 10, 441-75  | 14.4 | 168       |
| 64 | 1-(m-chlorophenyl)-biguanide, a potent high affinity 5-HT <sub>3</sub> receptor agonist. <i>European Journal of Pharmacology</i> , <b>1990</b> , 182, 193-7  | 5.3  | 153       |
| 63 | Urocortin, a novel neuropeptide with anxiogenic-like properties. <i>NeuroReport</i> , <b>1997</b> , 8, 1697-701  | 1.7  | 151       |
| 62 | GR205171: a novel antagonist with high affinity for the tachykinin NK <sub>1</sub> receptor, and potent broad-spectrum anti-emetic activity. <i>Regulatory Peptides</i> , <b>1996</b> , 65, 45-53  |      | 128       |
| 61 | The distribution of specific binding of the 5-HT <sub>3</sub> receptor ligand [3H]GR65630 in rat brain using quantitative autoradiography. <i>Neuroscience Letters</i> , <b>1988</b> , 94, 156-60  | 3.3  | 111       |
| 60 | CNS 7056: a novel ultra-short-acting Benzodiazepine. <i>Anesthesiology</i> , <b>2007</b> , 107, 60-6   | 4.3  | 110       |
| 59 | Morphine-6-glucuronide: actions and mechanisms. <i>Medicinal Research Reviews</i> , <b>2005</b> , 25, 521-44   | 14.4 | 107       |
| 58 | Consensus meeting agrees distribution of 5-HT <sub>3</sub> receptors in mammalian hindbrain. <i>Trends in Pharmacological Sciences</i> , <b>1990</b> , 11, 135-7   | 13.2 | 104       |
| 57 | A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. <i>Anesthesia and Analgesia</i> , <b>2012</b> , 115, 274-83 | 3.9  | 102       |

|    |   |      |     |
|----|---|------|-----|
| 56 | Cloning and characterisation of the human 5-HT <sub>5A</sub> serotonin receptor. <i>FEBS Letters</i> , <b>1994</b> , 355, 242-6   | 3.8  | 101 |
| 55 | Molecular biology of the CRH receptors-- in the mood. <i>Peptides</i> , <b>2001</b> , 22, 753-60  | 3.8  | 100 |
| 54 | The pharmacological characterization of 5-HT <sub>3</sub> receptors in three isolated preparations derived from guinea-pig tissues. <i>British Journal of Pharmacology</i> , <b>1990</b> , 101, 591-8   | 8.6  | 98  |
| 53 | 7TM receptors: the splicing on the cake. <i>Trends in Pharmacological Sciences</i> , <b>1999</b> , 20, 294-301  | 13.2 | 96  |
| 52 | The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. <i>British Journal of Pharmacology</i> , <b>1995</b> , 116, 3158-63   | 8.6  | 96  |
| 51 | Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. <i>Biochemical Pharmacology</i> , <b>1985</b> , 34, 2755-63   | 6    | 86  |
| 50 | A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , <b>1997</b> , 1352, 129-32  |      | 85  |
| 49 | Thioperamide, the selective histamine H <sub>3</sub> receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. <i>European Journal of Pharmacology</i> , <b>1994</b> , 259, 107-14   | 5.3  | 82  |
| 48 | A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. <i>Anesthesia and Analgesia</i> , <b>2012</b> , 115, 284-96 | 3.9  | 71  |
| 47 | Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. <i>Psychopharmacology</i> , <b>1984</b> , 84, 512-9  | 4.7  | 68  |
| 46 | Brain uptake and receptor binding of two [ <sup>11</sup> C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171--PET studies in rhesus monkey. <i>Neuropharmacology</i> , <b>2000</b> , 39, 664-70   | 5.5  | 61  |
| 45 | Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat. <i>Psychopharmacology</i> , <b>1984</b> , 84, 503-11   | 4.7  | 56  |
| 44 | Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. <i>Neuroscience Letters</i> , <b>1989</b> , 101, 305-10  | 3.3  | 54  |
| 43 | Histamine H <sub>3</sub> receptor-mediated modulation of water consumption in the rat. <i>European Journal of Pharmacology</i> , <b>1993</b> , 232, 99-103  | 5.3  | 53  |
| 42 | Characterization of histamine-H <sub>3</sub> receptors controlling non-adrenergic non-cholinergic contractions of the guinea-pig isolated ileum. <i>British Journal of Pharmacology</i> , <b>1992</b> , 105, 667-74   | 8.6  | 53  |
| 41 | Do thermodynamic studies provide information on both the binding to and the activation of dopaminergic and other receptors?. <i>Biochemical Pharmacology</i> , <b>1987</b> , 36, 4041-6   | 6    | 53  |
| 40 | A novel series of arylpiperazines with high affinity and selectivity for the dopamine D <sub>3</sub> receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>1995</b> , 5, 219-222   | 2.9  | 52  |
| 39 | Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay. <i>Neuropharmacology</i> , <b>1999</b> , 38, 441-8  | 5.5  | 47  |

|    |   |     |    |
|----|---|-----|----|
| 38 | Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin. <i>Neuropharmacology</i> , <b>1997</b> , 36, 1439-46  | 5.5 | 40 |
| 37 | The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile. <i>Journal of Neurochemistry</i> , <b>1999</b> , 73, 821-9 | 6   | 39 |
| 36 | Characterization of 5-HT <sub>3</sub> receptors in intact N1E-115 neuroblastoma cells. <i>European Journal of Pharmacology</i> , <b>1990</b> , 189, 223-7   |     | 39 |
| 35 | Identification and distribution of 5-HT <sub>3</sub> recognition sites within the human brainstem. <i>Neuroscience Letters</i> , <b>1990</b> , 111, 80-6  | 3.3 | 38 |
| 34 | Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 605170  | 8.4 | 38 |
| 33 | In vivo occupancy of histamine H <sub>3</sub> receptors by thioperamide and (R)-alpha-methylhistamine measured using histamine turnover and an ex vivo labeling technique. <i>Biochemical Pharmacology</i> , <b>1992</b> , 44, 1261-7                                   | 6   | 36 |
| 32 | Interactions between 5-HT <sub>3</sub> receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. <i>Psychopharmacology</i> , <b>1993</b> , 112, S68-75  | 4.7 | 36 |
| 31 | Labelling of 5-HT <sub>3</sub> receptor recognition sites in the rat brain using the agonist radioligand [3H]meta-chlorophenylbiguanide. <i>European Journal of Pharmacology</i> , <b>1993</b> , 243, 13-8  | 5.3 | 35 |
| 30 | [3H] GR67330, a very high affinity ligand for 5-HT <sub>3</sub> receptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1990</b> , 342, 22-30   | 3.4 | 32 |
| 29 | Inter-species variants of the 5-HT <sub>3</sub> receptor. <i>Biochemical Society Transactions</i> , <b>1992</b> , 20, 118-21  | 5.1 | 31 |
| 28 | The pharmacological characterization of 5-HT <sub>3</sub> receptor binding sites in rabbit ileum: Comparison with those in rat ileum and rat brain. <i>Neurochemistry International</i> , <b>1991</b> , 19, 389-396   | 4.4 | 31 |
| 27 | Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. <i>Oncology</i> , <b>1996</b> , 53 Suppl 1, 102-9   | 3.6 | 29 |
| 26 | Characterization of [3H]meta-chlorophenylbiguanide binding to 5-HT <sub>3</sub> receptors in N1E-115 neuroblastoma cells. <i>European Journal of Pharmacology</i> , <b>1993</b> , 243, 7-11   | 5.3 | 28 |
| 25 | [3H]SCH 23390 identifies D-1 binding sites in rat striatum and other brain areas. <i>Journal of Pharmacy and Pharmacology</i> , <b>1986</b> , 38, 907-12  | 4.8 | 27 |
| 24 | Interaction of neuroleptic drugs with rat striatal D-1 and D-2 dopamine receptors: a quantitative structure-affinity relationship study. <i>European Journal of Medicinal Chemistry</i> , <b>1988</b> , 23, 173-182   | 6.8 | 27 |
| 23 | Evidence for the abundant expression of arginine 185 containing human CRF(2alpha) receptors and the role of position 185 for receptor-ligand selectivity. <i>Neuropharmacology</i> , <b>2000</b> , 39, 1368-76  | 5.5 | 26 |
| 22 | 5-HT <sub>3</sub> and 5-HT <sub>4</sub> receptors in terminal regions of the mesolimbic system. <i>Behavioural Brain Research</i> , <b>1996</b> , 73, 11-3  | 3.4 | 25 |
| 21 | Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs. <i>Journal of Neural Transmission</i> , <b>1985</b> , 62, 249-66  | 4.3 | 24 |

|    |   |     |    |
|----|---|-----|----|
| 20 | Novel 6-substituted 2-aminotetralins with potent and selective affinity for the dopamine D3 receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>1996</b> , 6, 403-408                                | 2.9 | 23 |
| 19 | A post-synaptic depressant modulatory action of 5-hydroxytryptamine on excitatory amino acid responses in rat entorhinal cortex in vitro. <i>Neuropharmacology</i> , <b>1992</b> , 31, 531-9                      | 5.5 | 23 |
| 18 | The distribution of 5-HT <sub>3</sub> recognition sites in the marmoset brain. <i>European Journal of Pharmacology</i> , <b>1992</b> , 215, 63-7  | 5.3 | 20 |
| 17 | Pharmacological analysis of <sup>125</sup> I-Bolton and Hunter labelled eledoisin binding sites in rat spinal cord by quantitative autoradiography. <i>Neuroscience Letters</i> , <b>1987</b> , 78, 12-6          | 3.3 | 16 |
| 16 | Properties of rat striatal D-2 dopamine receptors solubilized with the zwitterionic detergent CHAPS. <i>Journal of Pharmacy and Pharmacology</i> , <b>1985</b> , 37, 320-8  | 4.8 | 15 |
| 15 | Characterisation of the specific binding of the histamine H <sub>3</sub> receptor antagonist radioligand [ <sup>3</sup> H]GR168320. <i>European Journal of Pharmacology</i> , <b>1996</b> , 311, 305-10           | 5.3 | 13 |
| 14 | Drug development in anaesthesia: industrial perspective. <i>Current Opinion in Anaesthesiology</i> , <b>2006</b> , 19, 385-9  | 2.9 | 12 |
| 13 | GR-68755 Hydrochloride. <i>Drugs of the Future</i> , <b>1992</b> , 17, 660  | 2.3 | 12 |
| 12 | Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures   |     | 11 |
| 11 | Pharmacological characterisation of the recombinant human CRF binding protein using a simple assay. <i>Journal of Neuroscience Methods</i> , <b>1998</b> , 80, 99-105   | 3   | 10 |
| 10 | Specific [ <sup>3</sup> H]piflutixol binding to CHAPS-solubilised rat striatal preparations involves dopamine D-2 but not D-1 binding sites. <i>Journal of Neurochemistry</i> , <b>1986</b> , 46, 413-21          | 6   | 10 |
| 9  | Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 690875  | 5.6 | 9  |
| 8  | A pharmacological comparison of [ <sup>3</sup> H]-granisetron binding sites in brain and peripheral tissues of the mouse. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1995</b> , 351, 221-8        | 3.4 | 8  |
| 7  | Target size of 5-HT <sub>3</sub> receptors in N1E-115 neuroblastoma cells and rat brain. <i>European Journal of Pharmacology</i> , <b>1990</b> , 189, 229-32  |     | 8  |
| 6  | The influence of aromatic substituents on the binding of substituted benzamides to dopamine D-2 receptors: congruent QSAR and MEP analyses. <i>Journal of Pharmacy and Pharmacology</i> , <b>1987</b> , 39, 767-8 | 4.8 | 5  |
| 5  | [ <sup>125</sup> I]Spiperone is not a useful ligand for studying the CHAPS solubilized dopamine D-2 receptor from rat striatum. <i>Journal of Pharmacy and Pharmacology</i> , <b>1986</b> , 38, 406-8             | 4.8 | 5  |
| 4  | 5-HT <sub>3</sub> receptor antagonists. <i>Expert Opinion on Investigational Drugs</i> , <b>1999</b> , 8, 2183-2188   | 5.9 | 5  |
| 3  | Urocortin: slower dissociation than corticotropin releasing factor from the CRF binding protein. <i>European Journal of Pharmacology</i> , <b>1999</b> , 376, 321-4   | 5.3 | 5  |

|   |  |     |   |
|---|--|-----|---|
| 2 | Effects of continuous administration for 12 months of amine-depleting drugs and chlorpromazine on striatal dopamine function in the rat. <i>Neuropharmacology</i> , <b>1987</b> , 26, 1061-9 | 5-5 | 3 |
| 1 | The binding of [3H]N-(chloroethyl)-norapomorphine to rat striatal membranes. <i>European Journal of Pharmacology</i> , <b>1984</b> , 107, 71-8   | 5-3 | 1 |